Sulzer Medica on upward trend
This article was originally published in Clinica
Executive Summary
Sulzer Medica plans to continue the growth of last year through product developments and acquisitions. The company's "dual strategy" has been facilitated through the company's partial flotation in Switzerland and the US last summer, which raised over $500 million. It is possible that its parent company Sulzer may sell off a second share of its subsidiary, Sulzer Medica to raise additional funds.
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.